Drug Profile
Research programme: anti-angiogenesis monoclonal antibodies - Xenova Group/Schering AG
Alternative Names: Anti-angiogenesis monoclonal antibodies research programme - KS Biomedix/Schering AGLatest Information Update: 28 Jul 2004
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma; Xenova Group
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Jul 2004 Discontinued - Preclinical for Cancer in Germany (unspecified route)
- 28 Jul 2004 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 25 Sep 2003 KS Biomedix Holdings has been acquired by Xenova Group